Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health, Inc. (Nasdaq: GH) is a precision oncology company that regularly issues news about its blood and tissue tests, real-world data initiatives, and AI analytics in cancer care. This news page aggregates company announcements, press releases, and other updates so readers can follow how Guardant’s technologies are being used in screening, monitoring, and treatment selection for cancer.
Recent Guardant Health news has covered topics such as preliminary financial results and test volumes, payer coverage milestones for the Shield blood test for colorectal cancer screening, and collaborations aimed at expanding access to oncology clinical trials. The company also reports on scientific presentations that highlight the performance of Guardant Reveal for minimal residual disease detection and therapy response monitoring, and Guardant360 Liquid for multiomic profiling and breast cancer subtyping.
Guardant’s updates frequently describe how its tests are applied across all stages of care, including early detection, recurrence monitoring, and advanced cancer management. News items also include information about partnerships with hospitals and research centers, participation in healthcare and investor conferences, and initiatives related to data infrastructure and AI-ready environments for large-scale genomic datasets.
Investors, clinicians, researchers, and others interested in Guardant Health can use this page to review the company’s latest press releases and historical announcements. By browsing this feed, readers can see how Guardant’s portfolio of liquid biopsy and precision oncology diagnostics is being deployed in clinical practice, research collaborations, and broader efforts to improve access to cancer screening and personalized treatment.
Guardant Health (NASDAQ:GH) has acquired the remaining shares of Guardant Health AMEA, Inc. from SoftBank for approximately $177.8 million, achieving full operational control in the Asia, Middle East, and Africa regions. This strategic move allows Guardant Health to enhance its response to the significant cancer burden in these areas, where over half of the world's new cancer cases arise. The company aims to expedite the adoption of its blood tests, notably the Guardant360 CDx, following regulatory approval in Japan.
Guardant Health, Inc. (Nasdaq: GH), a leader in precision oncology, will participate in two upcoming investor conferences. The first is the William Blair 42nd Annual Growth Stock Conference in Chicago on June 7 at 11:20 a.m. CT. The second is the Goldman Sachs 43rd Annual Global Healthcare Conference in Rancho Palos Verdes on June 14 at 9:20 a.m. PT. Live and archived webcasts will be available on the company's website. Guardant Health focuses on advanced cancer tests to improve patient outcomes and reduce healthcare costs.
Guardant Health (Nasdaq: GH) has launched the first blood-based cancer testing services in Europe at the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona. This partnership, established in January 2021, aims to enhance access to Guardant’s liquid biopsy technology. The service provides comprehensive genomic profiling to identify actionable biomarkers quickly from a blood draw, aiding in treatment decisions for late-stage cancer patients. With over 282,000 new cancer cases reported in Spain in 2020, this innovation seeks to improve patient outcomes through precision oncology.
Guardant Health will present new data at the 2022 ASCO Annual Meeting, taking place from June 3-7 in Chicago. Highlights include an oral presentation utilizing real-world data from GuardantINFORM to identify resistance to early treatment in advanced breast cancer and an updated progression-free survival analysis of fulvestrant plus capivasertib versus fulvestrant plus placebo in metastatic breast cancer. The company aims to demonstrate the utility of blood tests in optimizing patient care and improving outcomes.
Guardant Health's blood-based multimodal test demonstrated 100% sensitivity for colorectal cancer (CRC) at 90% specificity in a study of 557 participants presented at Digestive Disease Week 2022.
The updated assay integrates genomics and epigenomics. With a median participant age of 55, the test identifies CRC effectively, showcasing 90% sensitivity at 90% specificity and 88% at 95%. This innovative screening method aims to improve early detection rates, potentially increasing adherence to screening guidelines.
Guardant Health, Inc. (Nasdaq: GH) reported Q1 2022 revenue of $96.1 million, a 22% increase from the previous year. Clinical testing volumes surged 47% and biopharma volumes rose 45%. Gross profit reached $64.1 million, with a gross margin of 67%. However, operating expenses also increased by 19% to $187.5 million, leading to a net loss of $123.2 million for the quarter. The company maintains guidance for full-year 2022 revenue of $460 million to $470 million, reflecting 23% to 26% growth.
Fanatics has appointed Lydia Jett and Jonathan Mildenhall to its board of directors, bringing extensive experience from fintech, e-commerce, and marketing sectors. Jett, from SoftBank, played a crucial role in Fanatics' growth since their initial $1 billion investment in 2017. Mildenhall, former CMO of Airbnb, is noted for transforming brand strategies. Both directors will guide Fanatics in expanding its diverse portfolio, which includes licensed merchandise, digital collectibles, and online sports betting. Additionally, Fanatics released its first ESG report, highlighting its commitment to sustainability and social responsibility.
Guardant Health has launched Shield, a blood-based test aimed at early-stage colorectal cancer (CRC) detection, targeting adults aged 45 and older who are not current with screening guidelines. The test boasts a sensitivity of 91% for CRC and 20% for advanced adenomas with a specificity of 92%. This innovative screening method addresses compliance barriers associated with traditional methods like colonoscopy, offering a simple blood draw with no preparation required. Shield is now available by prescription through healthcare providers.
Guardant Health, a leading precision oncology firm, will participate in the BofA Securities 2022 Healthcare Conference in Las Vegas on May 10. The management team is set to engage in a fireside chat at 10:40 a.m. Pacific Time. Investors can access a live and archived webcast through the company’s website. Guardant Health focuses on revolutionizing cancer care with proprietary tests like Guardant360 and Guardant Reveal, aiming to enhance patient outcomes and reduce healthcare costs.
Guardant Health (Nasdaq: GH) will release its financial results for Q1 2022 on May 5, 2022, after market close. A conference call for investors will follow at 1:30 p.m. PT / 4:30 p.m. ET. The call can be accessed via the company’s website, where an archive will be available post-event. Guardant Health specializes in precision oncology, offering advanced tests for cancer patients and driving initiatives to improve clinical outcomes and reduce healthcare costs.